journal article·2019-12-04Open access

Relationship between the expressions of PD-L1 and tumour-associated fibroblasts in gastric cancer

Linsong Mu, Wentao Yu, Hailong Su, Yang Lin, Wu Sui, Xiang Yu, Chengkun Qin

Abstract

Previous studies have focused on the changes of tumour cells in immune escape, and less is known about the effect of tumour microenvironment (TME) on immune escape. Tumour-associated fibroblasts (TAF) is an important part of the TME and has special physiological and biochemical characteristics, but the specific mechanism has not been clarified. In order to investigate the effect of TAF on the expression of PD-L1 in gastric cancer cells, gastric cancer cell lines MNK45, SGC7901 were non-contact co-culturing with TAF 1, 3 and 7 d via transwell. PD-L1 mRNA and protein expression were detected using qRT-PCR and FCM. Then, 95 cases of gastric cancer tissues were selected and evaluated PD-L1 and TAF expressions by immunohistochemical examination. The results showed that the mRNA and protein expression of PD-L1 in the experiment group were significantly higher than that in the control group. PD-L1 expression was associated with massive lymphocyte infiltration, diffuse/mixed histology and intratumoral TAFs in gastric cancers. In conclusion, TAFs promoted the growth in gastric cancer cell lines by increased the PD-L1 expression.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Cancer Immunotherapy and Biomarkers · Cancer Cells and Metastasis · Immune cells in cancer

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of General Surgery, Shandong Provincial Hospital Affiliated to Shandong University

Department of General Surgery, The Affiliated Yantai Yuhuangding Hospital of Qingdao University

Department of Hepatological Surgery, Shandong Provincial Hospital affiliated to Shandong University

References (50)

Show source-provided references
1. 10.3322/caac.2010710.3322/caac.20107 ↗
2. 10.1016/j.hemonc.2018.03.00210.1016/j.hemonc.2018.03.002 ↗
3. 10.1016/j.bbrc.2018.07.01610.1016/j.bbrc.2018.07.016 ↗
4. 10.1038/sj.bjc.660554310.1038/sj.bjc.6605543 ↗
5. 10.1016/j.biopha.2018.07.06110.1016/j.biopha.2018.07.061 ↗
6. 10.1016/j.suronc.2018.08.00410.1016/j.suronc.2018.08.004 ↗
7. 10.1016/j.nantod.2018.06.00810.1016/j.nantod.2018.06.008 ↗
8. 10.1016/j.gene.2017.10.01510.1016/j.gene.2017.10.015 ↗
9. 10.1016/j.pan.2018.07.01110.1016/j.pan.2018.07.011 ↗
10. 10.1002/path.410310.1002/path.4103 ↗
11. 10.1016/j.yexcr.2015.04.00110.1016/j.yexcr.2015.04.001 ↗
12. 10.4161/cam.2041910.4161/cam.20419 ↗
13. 10.3892/ijo.2011.90610.3892/ijo.2011.906 ↗
14. 10.1016/j.jconrel.2015.03.02310.1016/j.jconrel.2015.03.023 ↗
15. 10.1016/j.oraloncology.2012.12.01410.1016/j.oraloncology.2012.12.014 ↗
16. Zheng Z, Bu Z, Liu X, et al. Level of circulating PD-L1 expression in patients with advanced gastric cancer and its clinical implications. Chin J Cancer Res. 2014;26:104–111.
17. 10.1016/j.ejca.2013.07.00110.1016/j.ejca.2013.07.001 ↗
18. 10.1016/j.anndiagpath.2017.04.00710.1016/j.anndiagpath.2017.04.007 ↗
19. 10.1016/j.cllc.2018.04.01410.1016/j.cllc.2018.04.014 ↗
20. 10.1016/j.ygyno.2018.02.01310.1016/j.ygyno.2018.02.013 ↗
21. 10.1016/j.prp.2017.09.01210.1016/j.prp.2017.09.012 ↗
22. 10.1016/j.humpath.2015.09.00610.1016/j.humpath.2015.09.006 ↗
23. 10.1016/j.canlet.2017.06.03310.1016/j.canlet.2017.06.033 ↗
24. 10.1093/annonc/mdu45010.1093/annonc/mdu450 ↗
25. 10.1158/0008-5472.CAN-12-109710.1158/0008-5472.CAN-12-1097 ↗
26. 10.1016/j.biopha.2012.02.00110.1016/j.biopha.2012.02.001 ↗
27. 10.1093/annonc/mdq60410.1093/annonc/mdq604 ↗
28. 10.1007/s10456-014-9438-110.1007/s10456-014-9438-1 ↗
29. Noguchi E, Saito N, Kobayashi M, et al. Clinical significance of hepatocyte growth factor/c-Met expression in the assessment of gastric cancer progression. Mol Med Rep. 2015;11:3423–3431.
30. 10.1080/21691401.2017.135198310.1080/21691401.2017.1351983 ↗
31. 10.1155/2010/69516210.1155/2010/695162 ↗
32. 10.1016/j.cell.2005.02.03410.1016/j.cell.2005.02.034 ↗
33. 10.1038/bjc.2013.76810.1038/bjc.2013.768 ↗
34. Nakazawa K, Yashiro M, Hirakawa K. Keratinocyte growth factor produced by gastric fibroblasts specifically stimulates proliferation of cancer cells from scirrhous gastric carcinoma. Cancer Res. 2003;63:8848–8854.
35. 10.1186/1756-9966-29-6610.1186/1756-9966-29-66 ↗
36. 10.1002/ijc.2506010.1002/ijc.25060 ↗
37. 10.1080/21691401.2017.135531110.1080/21691401.2017.1355311 ↗
38. 10.1158/1078-0432.CCR-10-182410.1158/1078-0432.CCR-10-1824 ↗
39. 10.1038/nrc261810.1038/nrc2618 ↗
40. 10.1038/nm73010.1038/nm730 ↗
41. 10.1073/pnas.19246109910.1073/pnas.192461099 ↗
42. 10.1053/j.gastro.2013.05.01010.1053/j.gastro.2013.05.010 ↗
43. 10.1016/j.cell.2014.05.04510.1016/j.cell.2014.05.045 ↗
44. 10.1038/nature1401110.1038/nature14011 ↗
45. Zheng Z, Bu Z, Liu X, et al. Level of circulating PD-L1 expression in patients with advanced gastric cancer and its clinical implications. Clin J Cancer Res. 2014;26:104–111.
46. 10.1186/1471-2407-8-5710.1186/1471-2407-8-57 ↗
47. 10.1186/s12943-015-0421-210.1186/s12943-015-0421-2 ↗
48. Muro K, Bang Y, Shankaran V, et al. IBA15A phase IB study of pembrolizumab (PEMBRO;MK-3475) in patients (PTS) with advanced gastric cancer. Ann Oncol. 2014;(Suppl. 4):415–438.
49. 10.1182/blood-2008-12-19579210.1182/blood-2008-12-195792 ↗
50. 10.1016/j.oraloncology.2011.08.00710.1016/j.oraloncology.2011.08.007 ↗